Protein Microarray Service
Protein arrays technology was developed in the early 2000s to do multiplexed protein measurements to explore protein function, protein-protein interactions, and modeling networks and pathways with the same throughput as DNA arrays.
Protein Microarray
Protein microarray, also known as protein chips, is a recently developed proteomic tool for characterizing the interactions, functions, and activities of proteins in a high-throughput manner. These tests can be scaled down to fit on chips designed for running on protein microarrays. The ability of protein microarrays to examine interactions between the nucleus and proteins, as well as interactions between proteins themselves, as well as interactions between ligands and receptors, drug targets, and protein substrates on a large scale, is one reason for their growing popularity. Briefly, protein microarrays are classified as target microarrays, reverse-phase protein arrays (RPPA), and in situ expressed arrays.
Fig.1 Types of protein arrays. (Dasilva, 2014)
- Target Microarray
The most frequent type of target microarray is an antibody microarray. Target microarrays are made up of various proteins printed onto a planar-solid surface. Since they allow the detection of specific protein profiles, these arrays have been found in various applications in clinical studies.
- RPPA
Affinity reagents, such as antibodies, single-chain variable fragments, and aptamers, are used to further identify the proteins captured by RPPA from cellular or tissue lysate samples or presenting in serum or plasma on the surface. As a result, the signal may be related to detecting a particular protein and may be influenced by the accessibility of the epitope and antibody affinities.
Fig.2 Overview of the RPPA workflow. (Coarfa, 2021)
- In situ Expressed Array
In situ expressed protein arrays are characterized for in vivo transcription-translation protein expression at the moment of the assay by using cell-free expression systems such as Escherichia coli, HeLa cell lysates, or rabbit reticulocyte lysates. This array requires a complementary DNA clone collection, which codifies proteins of interest and tags in the carboxy or amino terminus.
Published Data
| Paper Title | Comprehensive molecular portraits of invasive lobular breast cancer |
| Journal | Cell |
| Published | 2015 |
| Abstract | The second most common histologic subtype of invasive breast cancer is ILC (Invasive Lobular Cancer). They investigated 817 breast cancers in detail, including 127 ILC, 490 ductal (IDC, Invasive Ductal Carcinoma), and 88 mixed IDC/ILC. They also discovered ILC-related changes in PTEN, TBX3, and FOXA1. After PTEN deletion, ILC had the highest AKT phosphorylation. FOXA1 spatial mutations increased expression and activity. Luminal A IDC was defined by GATA3 mutations and high expression, implying that ILC and IDC modulate ER activity differently. Proliferation and immune-related markers revealed three ILC transcriptional subtypes associated with survival. Molecularly, mixed IDC/ILC cases revealed no hybrid traits. This multimodal molecular atlas sheds light on ILC genetics and provides clinical options. |
| Result |
A total of 817 breast tumor samples were profiled using 5 different platforms, with RPPA also profiling 633 cases. A pathology committee examined all tumors and classified them as 490 IDC, 127 ILC, 88 cases with mixed IDC and ILC features, and 112 as other histologies. In terms of previously reported RPPA-based subtypes, reactive-like ILC was largely, but not entirely, composed of reactive tumors, a subgroup distinguished by strong microenvironment and/or cancer fibroblast signaling.
|
Fig.3 ILC molecular subtypes. (Ciriello, 2015)
Creative Biolabs offers different panels of antibody combinations for the specific analysis of different biological processes, including cardiovascular disease panel, oncology panel, inflammation panel, nervous system panel, immuno-oncology transition panel, cell cycle regulation panel, cardiac metabolism panel, development biology panel, immune response panel, metabolism panel, neural exploration panel, and organ damage panel. For more information, please contact us.
References
- Dasilva, F.N.; et al. Emerging nanotechniques in proteomics. Comprehensive Analytical Chemistry. 2014, 63: 137-157.
- Coarfa, C.; et al. Reverse-phase protein array: technology, application, data processing, and integration. Journal of Biomolecular Techniques. 2021, 32(1): 15-29.
- Ciriello, G.; et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015, 163(2): 506-519.
